Search results
Results From The WOW.Com Content Network
Vitreomacular adhesion (VMA) is a human medical condition where the vitreous gel (or simply vitreous, AKA vitreous humour) of the human eye adheres to the retina in an abnormally strong manner. As the eye ages, it is common for the vitreous to separate from the retina.
Dogs with this kind of cancer that have surgery usually only survive 3 to 18 months, depending on how advanced the cancer is when found (1). Squamous cell carcinoma: This is a good possibility ...
Vitreomacular traction syndrome (VTS) is a medical condition in the eye that is the result of tractional forces (pulling) being placed on the retina. [ 1 ] [ 2 ] VTS is common in people who have an incomplete posterior vitreous detachment, a type of retinal detachment at the periphery of the retina. [ 1 ]
You are free: to share – to copy, distribute and transmit the work; to remix – to adapt the work; Under the following conditions: attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made.
Ocriplasmin, sold under the brand name Jetrea, is a recombinant protease with activity against fibronectin and laminin, components of the vitreoretinal interface.It is used for treatment of symptomatic vitreomacular adhesion, for which it received FDA approval on 17 October 2012.
Macular hole on the right eye Classification of Vitreomacular Adhesion, Traction, and Macular Hole (IVTS 2013). Macular degeneration is a condition affecting the tissues lying under the retina, while a macular hole involves damage from within the eye, at the junction between the vitreous and the retina itself.
Image credits: danngree People just seem to love dogs, and it’s estimated that over 65 million American households own one.It’s not just the fact that they look cute, but these pooches also ...
He has designed surgical instruments and holds several patents related to imaging technologies and treatments for retinal diseases. [17] [18] [19] [10] Dr. Spaide is affiliated with Vitreous Retina Macula Consultants of New York, where he continues his research and clinical work. [6] [3] [20] [9]